Concepts (51)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostate | 2 | 2022 | 422 | 0.230 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 1795 | 0.210 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2002 | 166 | 0.180 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2019 | 42 | 0.150 |
Why?
|
| Myeloid Cells | 1 | 2019 | 121 | 0.150 |
Why?
|
| Carcinoma, Papillary | 1 | 1999 | 161 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 1999 | 590 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2015 | 237 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2002 | 3142 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2022 | 403 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2002 | 83 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 393 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 346 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 9 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 38 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2019 | 47 | 0.040 |
Why?
|
| Cell Growth Processes | 1 | 2019 | 85 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 70 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 300 | 0.040 |
Why?
|
| Prognosis | 2 | 2015 | 4024 | 0.040 |
Why?
|
| Mitosis | 1 | 1999 | 159 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2022 | 480 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 1999 | 514 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 259 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 1999 | 280 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 205 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 706 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 1999 | 1194 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 855 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1461 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 568 | 0.030 |
Why?
|
| Medical Overuse | 1 | 2015 | 40 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2022 | 2478 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2019 | 2092 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2785 | 0.030 |
Why?
|
| Male | 3 | 2022 | 45735 | 0.020 |
Why?
|
| Humans | 5 | 2022 | 95971 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 1999 | 1662 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1957 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 487 | 0.020 |
Why?
|
| Aged | 2 | 2015 | 20877 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 10190 | 0.020 |
Why?
|
| Middle Aged | 2 | 2015 | 28255 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2002 | 25 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2002 | 73 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2002 | 79 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 242 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2002 | 109 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 358 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 930 | 0.010 |
Why?
|
| Female | 1 | 2002 | 49938 | 0.000 |
Why?
|